BRCA1 基因突变型家族性乳腺癌中的表观遗传变化。
Epigenetic changes in BRCA1-mutated familial breast cancer.
作者信息
Downs Bradley, Wang San Ming
机构信息
Department of Genetics, Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Department of Genetics, Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
出版信息
Cancer Genet. 2015 May;208(5):237-40. doi: 10.1016/j.cancergen.2015.02.001. Epub 2015 Feb 13.
Abstract
Familial breast cancer occurs in about 10% of breast cancer cases. Germline mutation in BRCA1 is the most penetrant predisposition for the disease. Mutated BRCA1 leads to disease by causing genome instability via multiple mechanisms including epigenetic changes. This review summarizes recent progress in studying the correlation between BRCA1 predisposition and epigenetic alterations in BRCA1-type familial breast cancer.
摘要
家族性乳腺癌约占所有乳腺癌病例的10%。BRCA1基因的种系突变是导致该疾病的最显著易感性因素。突变的BRCA1通过包括表观遗传变化在内的多种机制导致基因组不稳定，进而引发疾病。本文综述了BRCA1型家族性乳腺癌中BRCA1易感性与表观遗传改变之间相关性研究的最新进展。
相似文献
1
Epigenetic changes in BRCA1-mutated familial breast cancer.
Cancer Genet. 2015 May;208(5):237-40. doi: 10.1016/j.cancergen.2015.02.001. Epub 2015 Feb 13.
2
A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Am J Hum Genet. 2018 Aug 2;103(2):213-220. doi: 10.1016/j.ajhg.2018.07.002.
3
Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
PLoS One. 2016 Nov 30;11(11):e0165436. doi: 10.1371/journal.pone.0165436. eCollection 2016.
4
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Clin Breast Cancer. 2015 Dec;15(6):498-504. doi: 10.1016/j.clbc.2015.06.009. Epub 2015 Jun 18.
5
Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
Oncotarget. 2017 Jan 10;8(2):2850-2862. doi: 10.18632/oncotarget.13750.
6
DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.
Cell Mol Biol (Noisy-le-grand). 2016 Jan 11;62(1):16-23.
7
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.
8
First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
Oncotarget. 2015 Nov 3;6(34):35616-24. doi: 10.18632/oncotarget.5348.
9
Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.
Med Oncol. 2012 Sep;29(3):1561-8. doi: 10.1007/s12032-011-0100-0. Epub 2011 Nov 11.
10
A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
Clin Cancer Res. 2005 Feb 1;11(3):1146-53.
引用本文的文献
1
The Tumour Microenvironment and Epigenetic Regulation in Pathogenic Variant-Associated Breast Cancers.
Cancers (Basel). 2024 Nov 21;16(23):3910. doi: 10.3390/cancers16233910.
2
Selective Estrogen Receptor Modulators' (SERMs) Influence on Expression in Breast Cancer Cell Lines with Distinct Biological Subtypes.
Int J Mol Sci. 2024 Aug 6;25(16):8561. doi: 10.3390/ijms25168561.
3
BRCA1/2 mutations and outcomes among Middle Eastern patients with early-onset breast cancer in Oman.
Oncologist. 2024 Dec 6;29(12):e1714-e1722. doi: 10.1093/oncolo/oyae214.
4
Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
Int J Mol Sci. 2023 Apr 13;24(8):7235. doi: 10.3390/ijms24087235.
5
Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers.
Nucleic Acids Res. 2023 May 22;51(9):4341-4362. doi: 10.1093/nar/gkad172.
6
Highly diversified core promoters in the human genome and their effects on gene expression and disease predisposition.
BMC Genomics. 2020 Nov 30;21(1):842. doi: 10.1186/s12864-020-07222-5.
7
Regulation of DNA Damage Response and Homologous Recombination Repair by microRNA in Human Cells Exposed to Ionizing Radiation.
Cancers (Basel). 2020 Jul 8;12(7):1838. doi: 10.3390/cancers12071838.
8
Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.
Cells. 2020 May 8;9(5):1164. doi: 10.3390/cells9051164.
9
BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
PLoS One. 2017 Sep 1;12(9):e0184385. doi: 10.1371/journal.pone.0184385. eCollection 2017.
本文引用的文献
1
The prognostic value of promoter methylation in early stage triple negative breast cancer.
J Cancer Ther Res. 2014 Mar 19;3(2):1-11. doi: 10.7243/2049-7962-3-2.
2
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.
Genome Med. 2014 Jun 27;6(6):47. doi: 10.1186/gm567. eCollection 2014.
3
Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.
PLoS One. 2014 Jun 27;9(6):e100429. doi: 10.1371/journal.pone.0100429. eCollection 2014.
4
Histone demethylase KDM5B is a key regulator of genome stability.
Proc Natl Acad Sci U S A. 2014 May 13;111(19):7096-101. doi: 10.1073/pnas.1324036111. Epub 2014 Apr 28.
5
Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
Science. 2014 Mar 28;343(6178):1466-70. doi: 10.1126/science.1251827.
6
Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2013 Dec;142(3):619-27. doi: 10.1007/s10549-013-2774-9. Epub 2013 Nov 21.
7
Epigenetic interventions increase the radiation sensitivity of cancer cells.
Curr Pharm Des. 2014;20(11):1857-65. doi: 10.2174/13816128113199990529.
8
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
9
The oncogenic role of miR-155 in breast cancer.
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. Epub 2012 Jun 26.
10
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma.
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704. doi: 10.1073/pnas.1201516109. Epub 2012 Jun 8.
Zotero 插件